bctx stock

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of 'Eye-Bulging' Tumor

  • 12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors ( 1)
  • Top Responder: 21.4 months survival plus 100% resolution of ‘eye-bulging' orbital tumor
  • Compares to 7.2-9.8 months survival in historical comparison treatment trials ( 2)

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell's lead candidate Bria-IMT™ as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and Incyte's retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).

HLA-Typing : Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body's immune response. BriaCell's immunotherapy treatment appears most effective when the patient's HLA-type matches with Bria-IMT™, allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test.

Tumor Grade : BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell's treatment would be most effective.

BriaCell Treatment 1 Leading Treatment Comparison 2
N = Filter Prior Regimens Overall Survival vs. Prior Regimens Overall Survival
7 Combination Therapy 9 12.0 months 2 7.2 - 9.8 months
9 1+ HLA 8 12.1 months
5 2+ HLA 5 13.4 months
6 Tumor Grade I/II 12 12.5 months
Patient 06-005 3 2 HLA; Grade II 13 21.4 months

1) BriaCell treats severely sick patients, as indicated by the "Prior Regimens" column. To more accurately present survival data, BriaCell has included only those women able to mount an immune response. Patients from both the monotherapy and combination therapy are included unless otherwise indicated.
2) Overall survival of 7.2-9.8 months in similar patients with metastatic breast cancer who have failed 2 prior therapy attempts (third line setting); Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17.
3) Remarkable Responder highlighted; included within subsets "Tumor Grade I/II" and "2+ HLA".

Highlighting BriaCell's Top Responder :
Initially announced on Sep. 19, 2019 and subsequently on Jan. 13, 2020 , BriaCell has continued to emphasize this patient's positive response to BriaCell's treatment. Prior to BriaCell's treatment, the patient had received 12 regimens with 16 agents (incl. 13 chemotherapies), yet her condition worsened and included a gruesome orbital tumor that metastasized behind her left eye and caused the eye to bulge from its socket ( proptosis ).   After just six months of BriaCell's treatment, the orbital tumor had been completely eliminated, and she survived for over 21 months, a significant clinical benefit.

Figure 1: The figure shows MRI scans of the top responder patient. The arrows on the images (baseline scans) show the location of the orbital tumors. As shown on the images on the right hand side, the tumors were eliminated following 6 months of treatment with the Bria-IMT combination regimen.

In the figure above, and with tumors indicated by white arrows, complete resolution of the orbital tumor was observed after six months on BriaCell's treatment. Of note, she had two HLA matches with Bria-IMT™ and a grade II tumor, supporting BriaCell's hypotheses outlined above.

"Women with advanced breast cancer often are fighting a deadly disease that does not respond to currently-available treatments," said Dr. Bill Williams, BriaCell's President and CEO. "We are pleased to report that our immunotherapy regimen appears to offer clinical benefit for these patients in desperate need of new therapy options."

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

For additional information on BriaCell, please visit: .

Forward Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" and in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at and on EDGAR at . . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD

President & CEO

Media Relations:
Jules Abraham
Director of Public Relations

Investor Relations Contact:

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)


Keep reading...Show less


MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients

Exploratory Analysis Examines Effects of Otezla on Cardiometabolic Parameters

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Plant-Based Foods Inc.

Komo Plant Based Foods Inc. Announces Expanded Distribution Through Koyo Foods Inc.

Komo Plant Based Foods Inc. (CSE: YUM) (OTC Pink KOMOF) (FRA:9HB) ("Komo" or the "Company"), a premium plant-based food company, is proud to announce its alliance with Koyo Foods Inc., one of the largest health food distributors in Eastern Canada.

Koyo Foods Inc., renowned for its impressive range of over 2000 health and wellness products, will now include Komo's award-winning plant-based comfort foods in its distribution portfolio. This alliance marks an exciting milestone for Komo, expanding its reach to more consumers in Eastern Canada.

Keep reading...Show less


Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday May 31, 2023. David M. Reese M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

  • Special Shareholder Meeting to be Held in July 2023

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp. (" SpinCo "), a wholly-owned subsidiary of the Company (the " Arrangement Agreement ") pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the " SpinCo Assets "), will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia) (the " Arrangement ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has contracted Atheln Inc. (" Atheln "), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326 . Under the guidance of Monica Alfaro Welling Atheln will spearhead the project team to ensure the success of Sirona's meetings during the conference.

The primary focus of the contract is to meticulously prepare for the BIO International conference, where Sirona aims to establish valuable partnerships for the development and commercialization of TFC-1326. Recognizing the significance of these meetings, the collaboration with Atheln aims to maximize the probability of success. Sirona's team has secured numerous meetings with organizations and companies that possess complementary resources, capabilities, and a strategic interest in partnerships.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem Inc.

Keep reading...Show less

Latest Press Releases

Related News